Boggi Ugo, Vistoli Fabio, Signori Stefano, Del Chiaro Marco, Amorese Gabriella, Barsotti Massimiliano, Rizzo Gaetano, Marchetti Piero, Danesi Romano, Del Tacca Mario, Mosca Franco
Division of Surgery in Uremic and Diabetic Patients (General and Transplant Surgery), Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, Pisa, Italy.
Expert Opin Drug Saf. 2005 May;4(3):473-90. doi: 10.1517/14740338.4.3.473.
The efficacy and safety of basiliximab, in combination with different maintenance regimens, are extensively addressed in the available literature. Basiliximab reduces the incidence of acute rejection, allows a safe reduction of steroid dosage, and is associated with economic savings, although there is substantially no proof that basiliximab prolongs either patient or graft survival. Initial basiliximab administration entails a low-risk and is associated with fewer adverse events than T cell depleting agents. However, life-threatening reactions were reported following re-exposure to basiliximab in recipients who lost graft function early after transplantation and, therefore, discontinued all immunosuppressive agents.
巴利昔单抗与不同维持治疗方案联合应用的疗效和安全性在现有文献中已有广泛论述。巴利昔单抗可降低急性排斥反应的发生率，能安全地减少类固醇剂量，且可节省费用，尽管基本上没有证据表明巴利昔单抗能延长患者或移植物的存活时间。初始给予巴利昔单抗风险较低，与耗竭T细胞的药物相比，不良事件较少。然而，在移植后早期移植物功能丧失并因此停用所有免疫抑制剂的受者再次接触巴利昔单抗后，有危及生命的反应报道。
